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Abstract
Introduction and hypothesis—Understanding of pelvic floor disorders among women with 
gynecological cancer is limited. The objective of this study was to describe the prevalence of 
pelvic floor disorders in women with suspected gynecological malignancy before surgery.
Methods—A cross-sectional study was performed of women aged ≥18 with a suspected 
gynecological malignancy who enrolled in the University of North Carolina Health Registry/ 
Cancer Survivorship Cohort (HR/CSC) from August 2012 to June 2013. Demographics were 
obtained from the HR/CSC self-reported data; clinical data were abstracted from the electronic 
medical record. Subjects completed validated questionnaires (Rotterdam Symptom Checklist and 
the International Consultation on Incontinence Questionnaire-Female Lower Urinary Tract 
Symptoms) to assess bladder and bowel function.
Results—Among 186 women scheduled for surgery for gynecological malignancy, 152 (82 %) 
completed baseline assessments before surgery. Mean age was 58.1 ± 13.3 years, and mean BMI 
was 33.6 ± 8.8 kg/m2. The majority of subjects had uterine cancer (61.8 %), followed by ovarian 
(17.1 %) and cervical (11.1 %). At baseline, the rate of urinary incontinence (UI) was 40.9 %. A 
third of subjects reported stress UI, and one quarter reported urge UI. The overall rate of fecal 
incontinence was 3.9 %, abdominal pain was 47.4 %, constipation was 37.7 %, and diarrhea was 
20.1 %. When comparing cancer types, there were no differences in pelvic floor symptoms.
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Conclusion—Pelvic floor disorders are common in women with suspected gynecological 
malignancy at baseline before surgery. Recognizing pelvic floor disorders in the preoperative 
setting will allow for more individualized, comprehensive care for these women.
Keywords
Fecal incontinence; Gynecological cancer; Pelvic floor disorders; Urinary incontinence
Introduction
Quality of life is very important to women suffering from gynecological malignancies. 
Although eradicating disease is the primary focus of treatment, quality of life in the 
survivorship phase is an equally valued dimension of care for these women [1–3]. Pelvic 
floor disorders can be debilitating, and the associated psychological, emotional, and physical 
stressors have been shown to have a negative impact on women’s quality of life [4]. Women 
experiencing pelvic floor dysfunction often present with a myriad of symptoms, including 
pelvic organ prolapse, urinary incontinence (UI), fecal incontinence (FI), and sexual 
dysfunction. Because of a number of interacting factors, including social stigma and barriers 
to care, these disorders are not consistently reported by patients [5, 6].
Gynecological surgery, in addition to radiation and chemotherapy, has been recognized as a 
risk factor for pelvic floor dysfunction, but the extent of that risk for women with 
gynecological cancers has not been well elucidated [7–10]. One contributing factor is that 
screening for pelvic floor disorders in women with a gynecological malignancy is not 
common practice [11]. Given that the majority of women with a gynecological malignancy 
undergo surgical management and/or chemotherapy or radiation, these women may be at a 
higher risk of experiencing symptomatic pelvic floor dysfunction than the general 
population, and early diagnosis may be an opportunity to improve quality of life for these 
women following treatment.
While pelvic floor dysfunction has been identified as a problem frequently faced by 
survivors of gynecological cancer [12–14], the prevalence of pelvic floor dysfunction 
manifesting as UI, FI, and other bladder and bowel disorders in these women at baseline, 
before cancer treatment, remains unclear [15]. It is critical to identify the baseline rate of 
pelvic floor dysfunction in this at-risk population to provide comprehensive care to these 
women. Thus, the primary objective was to describe the prevalence of specific pelvic floor 
disorders in women with suspected gynecological malignancy at baseline before cancer 
treatment. Secondary objectives included assessing the effect of socio-demographic and 
clinical factors on the prevalence of these pelvic floor disorders.
Materials and methods
This was a cross-sectional, IRB-approved (IRB #13-2668) analysis of data collected for a 
large hospital database, the University of North Carolina at Chapel Hill (UNC) Health 
Registry/Cancer Survivorship Cohort (HR/CSC). The UNC HR/CSC integrates a 
comprehensive database of clinical, epidemiological, and patient interview data with 
repositories of biological specimens and tumor tissue. Patients are identified and recruited 
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through UNC Health Care outpatient oncology clinics and are recruited at the time of their 
new patient clinic visit. Eligible patients for the database must:
1. Be aged 18 years or over
2. Provide a North Carolina mailing address
3. Speak English or Spanish
Patients who were unable to provide informed consent or participate in interview 
questionnaires were excluded from participation in the HR/CSC. Trained staff conduct the 
interviews using a computer-assisted telephone interview software tool specifically 
developed for the HR/CSC. Interview questionnaire topics include medical and social 
history, and general and cancer-specific health assessments. Patient age and self-reported 
race/ethnicity are also included in the HR/CSC.
Inclusion criteria for this study were further restricted to HR/CSC patients recruited through 
the gynecological oncology clinic, who were referred for the assessment and treatment of 
suspected gynecological malignancies, and completed the baseline interviews, including 
cancer-site-specific questionnaires, before any cancer treatment. The study cohort included 
all subjects enrolled in the UNC HR/CSC database who presented for treatment of 
gynecological malignancies from August 2012 to June 2013. The electronic medical record 
was used to abstract relevant clinical data at the time of the new patient visit, including age, 
body mass index (BMI), comorbid conditions, mental health history, insurance status, and 
cancer site. The clinical data abstracted from the medical record were merged with the 
HR/CSC demographic and questionnaire data using an honest broker system. The HR/CSC 
subsequently provided a de-identified data set for our analysis.
Women completed baseline-condition-specific quality of life questionnaires for the HR/
CSC, including the Rotterdam Symptom Checklist (RSC) [16] and the International 
Consultation on Incontinence Questionnaire-Female Lower Urinary Tract Symptoms (ICIQ-
FLUTS) [17]. These questionnaires are validated to assess symptoms related to a broad 
range of symptoms experienced by cancer patients, including bladder and bowel 
dysfunction. Specifically, bladder symptoms include stress urinary incontinence (SUI), urge 
urinary incontinence (UUI), urgency, frequency, nocturia, and enuresis. Bowel symptoms 
include FI, abdominal pain, constipation, and diarrhea.
The RSC is a 39-item questionnaire used to measure a wide range of symptoms reported by 
cancer patients, including UI. The questionnaire also assesses bowel dysfunction such as 
abdominal pain, constipation, diarrhea, and leakage of stool. Severity of symptoms is 
measured using a four-point Likert-type scale that includes such items as physical distress, 
psychological distress, activity level, and overall quality of life over the past week. The rate 
of SUI was determined by a response of “yes” to “leaks when you cough and sneeze.” The 
rate of UUI was determines by a response of “yes” to “leaks before you can get to the 
toilet.” For the analysis of the effect of age on pelvic floor symptoms, RSC responses were 
considered to be present if subjects rated their symptoms as occurring “quite a bit” or “very 
much.”
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The ICIQ-FLUTS is a 12-item questionnaire, which evaluates female lower urinary tract 
symptoms and their impact on quality of life. Within the questionnaire there are three 
subscales that assess filling symptoms (nocturia, urgency, pain in bladder, and daytime 
frequency), leaking symptoms (UUI, SUI, unexplained incontinence, and enuresis), and 
voiding symptoms (hesitancy, straining, and interrupted stream). Symptom severity is graded 
on a ten-point Likert-type scale. The rate of SUI determined by a positive response to the 
question, “Does urine leak when you are physically active, exert yourself, cough or sneeze?” 
while the rate of UUI was determined by a positive response to the question, “Does urine 
leak before you can get to the toilet?” For the analysis of the effect of age on pelvic floor 
symptoms, ICIQ responses were considered to be present if subjects rated their symptoms as 
occurring “most of the time” or “all of the time.” The ICIQ-FLUTS survey was only 
provided to uterine and ovarian cancer patients as part of the cancer-site-specific survey.
The primary aim of this study was to report the prevalence of pelvic floor symptoms in a 
population of women with suspected gynecological malignancy. Thus, an a priori power 
calculation was not performed. Univariate summary statistics were generated using simple 
frequencies for categorical variables, and Student’s t test was used for the continuous 
variables of age and BMI. With regard to age, the distribution was confirmed to be normal 
via histogram, as well as Kolmogorov–Smirnov or Shapiro–Wilk tests. Secondary analyses 
were performed to compare symptom scores by age and by cancer site. Age was also 
dichotomized into > or < 50 years to estimate menopausal status. Fisher’s exact test was 
used to compare pelvic floor symptom scores by age > or < 50 years. Because each cancer 
type had relatively small numbers, the data were analyzed using nonparametric testing. 
Specifically, the Kruskal–Wallis test was used to compare these categorical data for multiple 
group comparisons. A p value < 0.05 was considered statistically significant. Data were 
analyzed using IBM SPSS version 18.0 (IBM SPSS, Chicago, IL, USA).
Results
Among 186 women with a suspected gynecological malignancy who enrolled in the 
HR/CSC during the study period, 152 (82 %) completed a baseline assessment before 
surgery. The majority of women were Caucasian, parous, post-menopausal, and had private 
insurance. The most common type of gynecological malignancy was uterine cancer, 
followed by ovarian, cervical, vulvar/vaginal, and other, which included gastrointestinal and 
unspecified gynecological cancer (Table 1). A small percentage of subjects had a 
gastrointestinal malignancy at the time of the final pathological assessment after surgery. 
Given that the women with primary gastrointestinal cancer underwent identical debulking 
procedures to the women diagnosed with ovarian cancer, they were included in the analysis.
Responses to the RSC questionnaire revealed a high prevalence of UI in this population 
(Table 2). ICIQ-FLUTS responses reflected a similarly high rate of urinary symptoms. 
Filling and leaking dysfunction were common, with a lower rate of voiding dysfunction in 
the study cohort. More than half of women reported symptoms of SUI (59.5 %), and more 
than one third reported UUI (33.9 %). There were no differences in urinary symptoms 
among cancer types, with relatively high rates of bladder dysfunction in all cancer types 
based on both RSC and ICIQ-FLUTS responses.
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Regarding bowel dysfunction, bothersome symptoms were reported in the study cohort 
(Table 2). Although the overall rate of FI was low, half of the women rated their symptoms 
“somewhat” to “quite a bit” bothersome, and one third of women with constipation rated 
their symptoms as “quite a bit” or “very much” bothersome. Whereas there were relatively 
high rates of abdominal pain and constipation in all cancer types, there were no differences 
in any type of bowel dysfunction based on cancer type.
To assess the impact of age on pelvic floor disorders, the cohort was divided into women age 
< 50 versus ≥ 50 years, approximating the age of menopause. Based on age, there were 
differences seen in the rates of abdominal pain, constipation, pain in bladder, and urge 
incontinence (leakage before getting to the toilet; Table 3). When modeling age as a 
continuous variable, there were no differences in bladder or bowel function.
Discussion
The objective of this study was to describe the prevalence of pelvic floor disorders in women 
with suspected gynecological malignancies at baseline before cancer surgery. In this study, 
the majority of women reported bothersome pelvic floor dysfunction at baseline before 
surgical treatment. These findings support the fact that pelvic floor disorders are a 
significant quality of life issue not only for survivors of gynecological malignancies, but also 
for women with suspected disease.
Interestingly, the rates of self-reported UI differed greatly between the two questionnaires 
used in this study. While the SUI rate reported by the ICIQ-FLUTS was nearly 60 %, the 
rate reported by the RSC was 40.1 %, which is closer to the previously reported rates in the 
general population [18]. While the ICIQ-FLUTS forms were only administered to uterine 
and ovarian cancer patients, this cannot fully explain the difference between the reported 
rates as the RSC rates of SUI reported by uterine and ovarian cancer patients was 32.0 %. 
While the reason for this difference is unclear, the ICIQ-FLUTS questionnaires were 
administered after the uterine and ovarian cancer patients had already provided responses to 
the RSC questionnaire, which may have introduced a form of bias. More studies are needed 
to evaluate whether cancer type affects the presentation of pelvic floor disorders in this 
population.
The prevalence of bothersome UI reported as “severe” in this study cohort was estimated at 
9.7 %, which is higher than the rate reported in the general population [19]. Many women 
diagnosed with gynecological cancer have complicated medical issues and often present 
with cancer-related symptoms such as bloating from ascites and mass effects from a tumor, 
which can exacerbate preexisting pelvic floor dysfunction and in turn may explain the higher 
rate of bothersome UI in this population. In a similar vein, while the rate of FI in this study 
at 3.7 % was lower than the overall prevalence of FI among women in the United States 
[20], the rate of bother related to this symptom was high. The low overall rate of FI in this 
study may be explained by the study’s sample size, and further studies are needed to better 
understand the impact of FI in this cohort of women.
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This study provides new information on baseline pelvic floor disorders in women with 
gynecological cancer—a clinical topic about which limited data are available. Other 
strengths of this study include the use of a robust database of condition-specific outcomes 
that were collected pre-treatment, eliminating the issue of recall bias. The questionnaires 
used in this study were validated and administered by trained staff, and the data collected 
through the questionnaires were patient-reported. Of note in the gynecological oncology 
setting, standardized questionnaires were found to be more effective in detecting 
symptomatic UI than provider evaluation alone [21].
A limitation of the study is that the findings were based on questionnaires rather than 
clinical examination; however, the study’s aim was to report on the symptoms of pelvic floor 
dysfunction, which is better identified with the use of questionnaires rather than by physical 
examination findings, as mentioned previously [21]. Also, the questionnaires used in this 
study were predetermined by the HR/CSC, and other questionnaires may capture the rates of 
symptomatic pelvic floor disorders in this population more accurately. Specifically, patients 
were not queried regarding bulge symptoms, which are indicative of prolapse, an important 
and often very bothersome pelvic floor disorder. The rates of pelvic floor prolapse in this 
population before treatment should be evaluated in future studies.
The study only includes those women who had consented via the HR/CSC and were 
scheduled for surgery as the primary treatment for their gynecological malignancy. Also, the 
study population was largely white and did not capture many Hispanic or Asian subjects, 
which limits the generalizability of the study’s findings. The study is also limited by a small 
sample size for each individual cancer type, which limited the power to detect differences 
between these groups. A post hoc power analysis revealed a 52 % power to detect a 
difference in pelvic floor symptoms based on cancer type, limiting the reliability of the lack 
of association we found between cancer site and symptoms. In addition, as the 
symptomatology of each cancer type differs, differences in the rates of pelvic floor disorders 
in these groups cannot be fully commented on based on the small sample size. 
Gynecological cancer treatment—surgery, chemotherapy and radiation—likely has a large 
impact on pelvic floor function, and there may also be an association between the underlying 
cancer disease process and the manifestation of pelvic floor disorders. More investigation is 
needed to determine whether there is a clinically significant difference in the presentation of 
symptomatic pelvic floor disorders depending on cancer type. Prospective studies are also 
needed to explore the impact of gynecological oncology treatments on pelvic floor function 
and pelvic health-related quality of life. Additionally, research is needed to determine which 
pelvic health questionnaires most effectively capture symptomatic pelvic floor dysfunction 
in this population, which patients would benefit from perioperative interventions for their 
pelvic floor disorders, and which interventions are most appropriate and effective for this 
cohort.
In conclusion, this study describes the rates of pelvic floor disorders in women with 
suspected gynecological malignancy before surgical management. The findings demonstrate 
that the rates of pelvic floor dysfunction are high in this population, with a higher prevalence 
of bladder dysfunction compared with bowel dysfunction. Given these findings, 
gynecological oncology providers should consider incorporating screening for pelvic floor 
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disorders as part of a comprehensive baseline evaluation before the initiation of cancer 
treatment. Furthermore, as pelvic health has a great impact on the quality of life for women 
with gynecological malignancies, awareness of these issues should be increased to allow for 
more individualized and comprehensive perioperative counseling and care for this special 
population.
References
1. Doll KM, Snavely AC, Kalinowski A, Irwin DE, Bensen JT, Bae-Jump V, Boggess JF, Soper JT, 
Brewster WR, Gehrig PA. Preoperative quality of life and surgical outcomes in gynecologic 
oncology patients: a new predictor of operative risk? Gynecol Oncol. 2014; 133(3):546–551. 
[PubMed: 24726615] 
2. Chase DM, Watanabe T, Monk BJ. Assessment and significance of quality of life in women with 
gynecologic cancer. Future Oncol. 2010; 6(8):1279–1287. [PubMed: 20799874] 
3. Penson RT, Wenzel LB, Vergote I, Cella D. Quality of life considerations in gynecologic cancer. 
FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer. Int J Gynaecol 
Obstet. 2006; 95(Suppl 1):S247–S257. [PubMed: 17161164] 
4. Herzog AR, Diokno AC, Brown MB, Fultz NH, Goldstein NE. Urinary incontinence as a risk factor 
for mortality. J Am Geriatr Soc. 1994; 42(3):264–268. [PubMed: 8120310] 
5. DeLancey JO. The hidden epidemic of pelvic floor dysfunction: achievable goals for improved 
prevention and treatment. Am J Obstet Gynecol. 2005; 192(5):1488–1495. [PubMed: 15902147] 
6. Hatchett L, Hebert-Beirne J, Tenfelde S, Lavender MD, Brubaker L. Knowledge and perceptions of 
pelvic floor disorders among African American and Latina women. Female Pelvic Med Reconstr 
Surg. 2011; 17(4):190–194. [PubMed: 22453850] 
7. Altman D, Falconer C, Cnattingius S, Granath F. Pelvic organ prolapse surgery following 
hysterectomy on benign indications. Am J Obstet Gynecol. 2008; 198(5):572.e1–e6. [PubMed: 
18355787] 
8. Jackson KS, Naik R. Pelvic floor dysfunction and radical hysterectomy. Int J Gynecol Cancer. 2006; 
16(1):354–363. [PubMed: 16445658] 
9. Thakar R, Sultan AH. Hysterectomy and pelvic organ dysfunction. Best Pract Res Clin Obstet 
Gynaecol. 2005; 19(3):403–418. doi: 10.1016/j.bpobgyn.2005.01.008. [PubMed: 15985255] 
10. Brooks RA, Wright JD, Powell MA, Rader JS, Gao F, Mutch DG, Wall LL. Long-term assessment 
of bladder and bowel dysfunction after radical hysterectomy. Gynecol Oncol. 2009; 114(1):75–79. 
[PubMed: 19410279] 
11. Rutledge TL, Heckman SR, Qualls C, Muller CY, Rogers RG. Pelvic floor disorders and sexual 
function in gynecologic cancer survivors: a cohort study. Am J Obstet Gynecol. 2010; 203(5):
514.e1–e7. [PubMed: 20869691] 
12. Nosti PA, Sokol AI. Unusual findings on cystoscopy in a patient with detrusor overactivity. Female 
Pelvic Med Reconstr Surg. 2012; 18(3):186–187. [PubMed: 22543775] 
13. Jensen PT, Groenvold M, Klee MC, Thranov I, Petersen MA, Machin D. Longitudinal study of 
sexual function and vaginal changes after radiotherapy for cervical cancer. Int J Radiat Oncol Biol 
Phys. 2003; 56(4):937–949. [PubMed: 12829128] 
14. Hazewinkel MH, Sprangers MA, van der Velden J, van der Vaart CH, Stalpers LJ, Burger MP, 
Roovers JP. Long-term cervical cancer survivors suffer from pelvic floor symptoms: a cross-
sectional matched cohort study. Gynecol Oncol. 2010; 117(2):281–286. [PubMed: 20170944] 
15. Thomas SG, Sato HR, Glantz JC, Doyle PJ, Buchsbaum GM. Prevalence of symptomatic pelvic 
floor disorders among gynecologic oncology patients. Obstet Gynecol. 2013; 122(5):976–980. 
[PubMed: 24104774] 
16. De Haes JC, van Knippenberg FC, Neijt JP. Measuring psychological and physical distress in 
cancer patients: structure and application of the Rotterdam Symptom Checklist. Br J Cancer. 1990; 
62(6):1034–1038. [PubMed: 2257209] 
17. Brookes ST, Donovan JL, Wright M, Jackson S, Abrams P. A scored form of the Bristol Female 
Lower Urinary Tract Symptoms questionnaire: data from a randomized controlled trial of surgery 
Bretschneider et al. Page 7
Int Urogynecol J. Author manuscript; available in PMC 2017 September 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
for women with stress incontinence. Am J Obstet Gynecol. 2004; 191(1):73–82. [PubMed: 
15295345] 
18. Nitti VW. The prevalence of urinary incontinence. Rev Urol. 2001; 3(Suppl 1):S2. [PubMed: 
16985992] 
19. Wu JM, Vaughan CP, Goode PS, Redden DT, Burgio KL, Richter HE, Markland AD. Prevalence 
and trends of symptomatic pelvic floor disorders in U.S. women. Obstet Gynecol. 2014; 123(1):
141–148. [PubMed: 24463674] 
20. Lawrence JM, Lukacz ES, Nager CW, Hsu JW, Luber KM. Prevalence and co-occurrence of pelvic 
floor disorders in community-dwelling women. Obstet Gynecol. 2008; 111(3):678–685. [PubMed: 
18310371] 
21. Del Priore G, Taylor SY, Esdaile BA, Masch R, Martas Y, Wirth J. Urinary incontinence in 
gynecological oncology patients. Int J Gynecol Cancer. 2005; 15(5):911–914. [PubMed: 
16174244] 
Bretschneider et al. Page 8
Int Urogynecol J. Author manuscript; available in PMC 2017 September 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Bretschneider et al. Page 9
Table 1
Overall characteristics of the study cohort
Characteristic n (%)
Age (years) 58.1 ± 13.3a
Race
 White 120 (79.0)
 Black 22 (14.5)
 Other 10 (6.5)
BMI (kg/m2) 33.6 ± 8.8a
Insurance status
 None 32 (21.0)
 Medicare only 5 (3.2)
 Medicaid 7 (4.6)
 Private 108 (71.0)
Substance use
 Tobacco 13 (8.6)
 Marijuana 1 (0.7)
 Polysubstance 4 (2.6)
Cancer site
 Uterine 94 (61.8)
 Ovarian 26 (17.1)
 Cervical 17 (11.1)
 Vulvar 9 (5.9)
 Gynecological, nitric oxide synthase 3 (2.0)
 Gastrointestinal 3 (2.0)
Stage
 I–II 98 (64.5)
 III–IV 46 (30.3)
 Unstaged 8 (5.3)
Route of surgery
 Minimally invasive 78 (52.7)
 Laparotomy 62 (41.9)
 Groin 8 (5.4)
aAnalysis performed using Student’s t test
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Table 2
Rate of pelvic floor symptoms by cancer type, based on the Rotterdam Symptom Checklist
Pelvic floor symptom Questionnaire response All, n (%) Uterine, n (%) Ovarian, n (%) Cervical, n (%) Vulvar/vaginal, n (%) p value
Any urinary incontinence Never 87 (59.6) 58 (62.4) 13 (48.1) 11 (64.7) 5 (55.6) 0.51
Once a week 15 (10.3) 12 (12.9) 3 (11.1) 0 (0) 0 (0)
2–3 times/week 19 (13.0) 8 (8.6) 7 (25.9) 4 (23.5) 0 (0)
Once a day 14 (9.6) 9 (9.7) 2 (7.4) 1 (5.9) 2 (22.2)
Several times a day 9 (6.2) 4 (4.3) 2 (7.4) 1 (5.9) 2 (22.2)
All the time 2 (1.4) 2 (2.2) 0 (0) 0 (0) 0 (0)
Stress urinary incontinence Yes 46 (74.2) 27 (77.1) 11 (78.6) 4 (50.0) 4 (80.0) 0.62
No 16 (25.8) 8 (22.9) 3 (27.3) 4 (50.0) 1 (20.0)
Urge urinary incontinence Yes 38 (67.9) 23 (67.6) 10 (71.4) 3 (60.0) 2 (66.7) 0.74
No 18 (32.1) 11 (32.4) 4 (28.6) 2 (40.0) 1 (33.3)
Abdominal pain Not at all 79 (53.4) 54 (56.8 ) 14 (51.9) 5 (2.9) 6 (66.7) 0.17
A little 44 (29.7) 31 (32.6) 3 (11.1) 7 (41.2) 3 (33.3)
Quite a bit 13 (8.8) 5 (5.3) 5 (18.5) 3 (17.6) 0 (0)
Very much 12 (8.1) 5 (5.3) 5 (18.5) 2 (11.8) 0 (0)
Constipation Not at all 85 (57.4) 60 (63.2 13 (48.1) 7 (41.2) 5 (55.6) 0.20
A little 43 (29.1) 25 (26.3) 9 (33.3) 7 (41.2) 2 (22.2)
Quite a bit 12 (8.1) 6 (6.3) 4 (14.8) 0 (0) 2 (22.2)
Very much 8 (5.4) 4 (4.2) 1 (3.7) 3 (17.6) 0 (0)
Diarrhea Not at all 118 (79.7) 76 (80.0) 21 (77.8) 15 (88.2) 6 (66.7) 0.82
A little 24 (16.2) 17 (17.9) 3 (11.1) 1 (5.9) 3 (33.3)
Quite a bit 1 (0.7) 0 (0) 1 (3.7) 0 (0) 0 (0)
Very much 5 (3.4) 2 (2.1) 2 (7.4) 1 (5.9) 0 (0)
Fecal incontinence Yes 5 (3.4) 3 (3.2) 1 (3.7) 1 (5.9) 0 (0) 0.27
No 142 (96.6) 91 (96.8) 26 (96.3) 16 (94.1) 9 (100)
All analyses performed using the Kruskal–Wallis test
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Table 3
Impact of age on urinary and bowel dysfunction
Pelvic floor symptom <50 years, n (%) ≥ 50 years, n (%) P value
Abdominal paina 11 (32.4) 16 (13.3) 0.01
Constipationa 8 (23.5) 14 (11.7) 0.01
Diarrheaa 1 (2.9) 6 (5.0) 0.78
Fecal incontinencea 2 (5.9) 4 (3.4) 0.62
Nocturiab 3 (20.0) 17 (17.0) 0.40
Enuresisb 1 (20.0) 4 (5.8) 0.09
Pain in bladderb 3 (20.0) 3 (3.0) 0.01
Leak before getting to toiletb 2 (13.4) 37 (37.0) 0.03
Leak with physical activityb 1 (20.0) 3 (4.3) 0.14
All data were analyzed using Fisher’s exact test
a
Based on the Rotterdam Symptom Checklist questionnaire
b
Based on International Consultation on Incontinence Questionnaire-Female Lower Urinary Tract Symptoms
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